• Lior mor
  • •
  • 6 Min Read
  • •
  • 19 minutes ago

SKN | Could McDonald’s $8.5 Billion Upgrade Plan Reshape Its Growth Story?

McDonald’s Unveils a More Expensive Growth Strategy McDonald’s shares fell 6% in afternoon trading after the company provided investors with…
SKN | Could McDonald’s $8.5 Billion Upgrade Plan Reshape Its Growth Story?
  • sagi habasov
  • •
  • 5 Min Read
  • •
  • 13 hours ago

SKN | Could BlackBerry’s Record QNX Design Win Strengthen Its Earnings Story?

BlackBerry is heading into its latest earnings report with a significant development in its automotive software business. Coretura, the commercial…
SKN | Could BlackBerry’s Record QNX Design Win Strengthen Its Earnings Story?
  • Ronny Mor
  • •
  • 5 Min Read
  • •
  • 13 hours ago

SKN | Could Darden’s Slowing Revenue Growth Put Pressure on Its Earnings Momentum?

Darden Restaurants is preparing to release its latest quarterly results Thursday morning, with investors assessing whether the company can sustain…
SKN | Could Darden’s Slowing Revenue Growth Put Pressure on Its Earnings Momentum?
  • omer bar
  • •
  • 4 Min Read
  • •
  • 14 hours ago

SKN | Could TD SYNNEX’s Strong Revenue Growth Keep the Stock’s Earnings Momentum Intact?

TD SYNNEX is approaching its latest earnings report with investors focused on whether the company can maintain the acceleration seen…
SKN | Could TD SYNNEX’s Strong Revenue Growth Keep the Stock’s Earnings Momentum Intact?
  • sagi habasov
  • •
  • 4 Min Read
  • •
  • 1 day ago

SKN | Can Aytu BioPharma’s Q4 Results Clarify Its Path Beyond Continued Losses?

Aytu BioPharma is set to release its fiscal fourth-quarter 2026 results after the U.S. market closes on September 22. The…
SKN | Can Aytu BioPharma’s Q4 Results Clarify Its Path Beyond Continued Losses?
  • Ronny Mor
  • •
  • 5 Min Read
  • •
  • 1 day ago

SKN | Could MillerKnoll’s Q1 Earnings Reveal Whether Margin Pressure Is Temporary?

MillerKnoll is heading into its fiscal first-quarter 2027 earnings release with investors closely watching whether demand and profitability can withstand…
SKN | Could MillerKnoll’s Q1 Earnings Reveal Whether Margin Pressure Is Temporary?
  • omer bar
  • •
  • 5 Min Read
  • •
  • 1 day ago

SKN | Could AutoZone’s Earnings Report Help the Stock Recover From a 52-Week Low?

AutoZone shares are heading into the company's fiscal fourth-quarter results under pressure after the stock reached a new 52-week low…
SKN | Could AutoZone’s Earnings Report Help the Stock Recover From a 52-Week Low?
  • sagi habasov
  • •
  • 5 Min Read
  • •
  • 2 days ago

SKN | Could Medicare GLP-1 Coverage Accelerate Eli Lilly’s Obesity Drug Growth?

Medicare Coverage Expands the GLP-1 Market Eli Lilly is seeing significant early demand from Medicare beneficiaries following the launch of…
SKN | Could Medicare GLP-1 Coverage Accelerate Eli Lilly’s Obesity Drug Growth?
  • omer bar
  • •
  • 5 Min Read
  • •
  • 2 days ago

SKN | Can Novo Nordisk’s Post-Wegovy Strategy Restore Investor Confidence?

Novo’s Long-Term Strategy Fails to Calm Investors Novo Nordisk shares came under heavy pressure Monday after the Danish drugmaker unveiled…
SKN | Can Novo Nordisk’s Post-Wegovy Strategy Restore Investor Confidence?
  • Arik Arkadi Sluzki
  • •
  • 5 Min Read
  • •
  • 4 days ago

SKN | Porsche Faces Potential 4,000 Job Cuts as Volkswagen Accelerates Restructuring Plan

  Volkswagen’s restructuring efforts are extending deeper into its premium automotive operations, with Porsche reportedly facing another round of workforce…
SKN | Porsche Faces Potential 4,000 Job Cuts as Volkswagen Accelerates Restructuring Plan
  • Ronny Mor
  • •
  • 5 Min Read
  • •
  • 5 days ago

SKN | Could Rising Oil Prices Trigger a New Global Interest Rate-Hiking Cycle?

Energy Shock Changes the Global Rate Outlook Financial markets are increasingly confronting the possibility of another period of coordinated monetary…
SKN | Could Rising Oil Prices Trigger a New Global Interest Rate-Hiking Cycle?
  • Lior mor
  • •
  • 5 Min Read
  • •
  • 7 days ago

SKN | Can Innate Pharma’s Sobi Partnership Strengthen Its Path Toward Late-Stage Cancer Treatments?

Innate Pharma enters the second half of 2026 with a reshaped financial and development strategy centered on advancing its cancer-immunotherapy…
SKN | Can Innate Pharma’s Sobi Partnership Strengthen Its Path Toward Late-Stage Cancer Treatments?

Hot Spot

Sectors Status

SectorWeight (%)YTD Return
All Sectors100.00%+15.04%
Technology33.60%+27.65%
Financial Services13.10%-0.27%
Industrials10.40%+42.58%
Healthcare9.25%+13.21%
Communication Services9.24%+2.04%
Consumer Cyclical8.98%-3.52%
Energy4.79%+33.93%
Consumer Defensive4.25%+4.68%
Basic Materials2.66%+14.02%
Real Estate1.95%+4.88%
Utilities1.79%-1.77%